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AbstrAct
Objectives Anxiety is more prevalent in children with 
chronic fatigue syndrome/myalgic encephalomyelitis (CFS/
ME) than in the general population. A systematic review 
was carried out to identify which treatment methods are 
most effective for children with CFS and anxiety.
Design Systematic review using search terms entered 
into the Cochrane library and Ovid to search the databases 
Medline, Embase and psychINFO.
Participants Studies were selected if participants were 
<18 years old, diagnosed with CFS/ME (using US Centers 
for Disease Control and Prevention, the National Institute 
for Health and Care Excellence or Oxford criteria) and had 
a valid assessment of anxiety.
Interventions We included observational studies and 
randomised controlled trials.
comparison Any or none.
Outcomes Change in anxiety diagnostic status and/
or change in anxiety severity on a validated measure of 
anxiety from pretreatment to post-treatment.
results The review identified nine papers from eight 
studies that met the inclusion criteria. None of the studies 
specifically targeted anxiety but six studies tested an 
intervention and measured anxiety as a secondary 
outcome. Of these studies, four used a cognitive 
behavioural therapy (CBT)-type approach to treat CFS/
ME, one used a behavioural approach and one compared 
a drug treatment, gammaglobulin with a placebo. Three of 
the CBT-type studies described an improvement in anxiety 
as did the trial of gammaglobulin. As none of the studies 
stratified outcomes according to anxiety diagnostic status 
or severity, we were unable to determine whether anxiety 
changed prognosis or whether treatments were equally 
effective in those with comorbid anxiety compared with 
those without.
conclusion We do not know what treatment should 
be offered for children with both anxiety and CFS/ME. 
Further research is therefore required to answer this 
question.
trial registration number This review was registered 
on Prospective Register of Systematic Review Protocols 
(PROSPERO) and the protocol is available from http://
www. crd. york. ac. uk/ PROSPERO/ display_ record. asp? ID= 
CRD42016043488.
bAckgrOunD
Chronic fatigue syndrome (CFS)/myalgic 
encephalomyelitis (ME) is a chronic condi-
tion of unknown aetiology consisting of 
disabling fatigue, malaise, difficulty sleeping, 
joint/muscle aches and difficulty concen-
trating.1 The prevalence of CFS/ME in teen-
agers varies from 0.5% to 2.4%, depending 
on the diagnostic criteria and methodology 
used.2–4 CFS/ME can have a very debilitating 
impact on children with one study showing 
a ≤40% school attendance rate in almost 
two-thirds (62%) of children with CFS/ME.5 
Furthermore, children with CFS/ME expe-
rience difficulty concentrating and impair-
ments in cognitive function which have a 
significant impact on their learning and 
education.6
Anxiety is a relatively common mental 
health condition; in the general population, 
it is estimated that 5%–19% of all children 
suffer from anxiety.7 Children with CFS/ME 
experience higher rates of anxiety than the 
normal population, with one study showing 
rates of 38% in teenage girls.8 Specifically, 
separation anxiety and social phobia were 
found to be the most prevalent subtypes 
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Research
strengths and limitations of this study
 ► This systematic review identified publications 
investigating the treatment of anxiety in 
children with chronic fatigue syndrome/myalgic 
encephalomyelitis .
 ► Each article was screened and the data were 
extracted independently by two reviewers.
 ► Foreign articles were included and translators were 
recruited to assist where necessary.
 ► However, the grey literature was not searched.
 ► The findings of the review are limited by the 
exclusion of children with high levels of anxiety from 
some treatment trials.
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of anxiety in paediatric CFS/ME.8 Children with a 
chronic illness might be more anxious as a reaction to 
being ill, the ‘threatening environment’ of a chronic 
illness or other psychological factors as a result of their 
condition.9
It is unclear as to whether children with CFS/ME 
develop anxiety as a result of their condition or whether 
psychological difficulties might pose a vulnerability to 
developing CFS/ME2 or whether an external factor 
might increase the likelihood of an individual developing 
both anxiety and CFS/ME. Being diagnosed with CFS/
ME has a substantial impact on social and academic life, 
which could potentially contribute to the development 
of distress, including depression and/or anxiety.10 This 
may be compounded by the stigma surrounding CFS/ME 
and the inability to fully explain this illness, resulting in 
uncertainty.10 11 It is also possible that a biological mecha-
nism is responsible for both the development of CFS/ME 
and anxiety, with some evidence of cortisol levels being 
implicated in CFS/ME in children and clear evidence of 
cortisol being linked to anxiety.12–14
Anxiety may have a negative impact on recovery in 
paediatric CFS/ME by affecting an individual’s ability to 
follow the evidence-based treatment for CFS/ME, which 
includes gradually increasing their activity levels. For 
example, in children, if the aim of treatment for CFS/
ME was to gradually increase school attendance; anxiety 
about going to school may prevent them from doing this. 
Therefore, comorbid anxiety may need to be a specific 
treatment target in paediatric CFS/ME. The aims of this 
review are to establish what is known about treatment 
approaches for anxiety in children with CFS/ME and 
what is known about the impact of comorbid anxiety on 
outcome in CFS/ME.
MethODs
Data sources and search strategy
The search strategy for this systematic review incorpo-
rated the use of the Cochrane library and OVID to search 
the databases Medline, Embase and psychINFO. The 
search strategy was designed with input from an informa-
tion specialist to include the concepts ‘paediatric’ and 
‘CFS/ME’. Limits were applied according to the inclu-
sion criteria. Final searches were conducted in July 2016. 
The full protocol can be found in Prospective Register 
of Systematic Review Protocols (PROSPERO) (http://
www. crd. york. ac. uk/ PROSPERO/ display_ record. asp? 
ID= CRD42016043488). The protocol was not revised 
after registration, although the search terms were slightly 
amended, and the final search terms are available as 
online supplementary information 1.
The grey literature was not searched, but the refer-
ence lists of all the included articles were hand searched. 
Foreign studies were considered for inclusion with the 
help of native speakers who assisted in the translation of 
these to determine whether the studies met the inclusion 
criteria.
Inclusion and exclusion criteria
Studies were included if they met the following criteria:
Participants
 ► Children <18 years of age;
 ► Diagnosed with CFS/ME defined using US Centers 
for Disease Control and Prevention (CDC) criteria15 
or the National Institute for Health and Care Excel-
lence (2007) or Oxford criteria.
Interventions
 ► Longitudinal study (treatment trial or observational 
cohort study).
Comparison
 ► Any or none.
Outcomes
 ► Study included a validated assessment of anxiety at 
baseline and repeated measures for either anxiety or 
fatigue on a validated scale.
Study selection
Initial screening was by title and abstract to assess eligi-
bility. Subsequently, full texts of the potentially eligible 
articles were reviewed to ascertain whether they met all 
the eligibility criteria. Two reviewers (from a pool of 
five reviewers, including SS, ML, VR, NL and AB) inde-
pendently assessed papers at each stage. Differences in 
opinion were resolved by discussion, overseen by EC, with 
reference to the review protocol.
Data extraction
For all included articles, data were extracted using a data 
extraction form, collecting information such as the CFS/
ME definition used, treatment/interventions provided, 
definition of response, details of the setting of the study, 
how children were recruited for the study, date of the 
study and child characteristics (including age). Three 
reviewers (SS, ML, NL) independently carried out this 
process.
Quality assessment
Two reviewers independently assessed the quality of the 
studies included using the Cochrane risk of bias assess-
ment tool as well as Critical Appraisal Skills Programme 
tools.16–18 This was done for both observational studies 
and randomised controlled trials (RCTs).
Data synthesis
There was insufficient comparable data to undertake 
a meta-analysis. Therefore, a narrative synthesis was 
undertaken.
results
Identification of studies
A total of 1274 records were found by database searching, 
and after duplicates were removed, 1074 remained 
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Figure 1 Systematic review flow chart (based on PRISMA guidelines).40 CDC, US Centers for Disease Control and Prevention; 
CFS, chronic fatigue syndrome; ME, myalgic encephalomyelitis; NICE, the National Institute for Health and Care Excellence; 
PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; RCT, randomised controlled trials.
(figure 1). Two hundred and twenty-three articles were 
reviewed in full; however, only nine papers were eligible 
from eight studies. One foreign paper (Spanish) was 
included in this review, and a further three were consid-
ered ineligible at full-text review (Dutch, German and 
Spanish).
Quality assessment
There were five observational studies and three RCTs 
that were included in this systematic review. Most of the 
studies had a clear focused aim, although none of the 
included studies specifically focused on change in anxiety 
in paediatric CFS/ME as their primary outcome. The 
participants were recruited in an acceptable way for most 
studies. The RCTs were judged most robust and least at 
risk of bias; the participant groups were comparable at 
the point of randomisation and the groups were also 
treated equally apart from the experimental treatment 
under investigation. One RCT used a placebo,19 while 
the other two used an active treatment comparison (treat-
ment as usual).6 20–22 For the observational studies, one 
was a case study, and therefore at high risk of bias.23 For 
the remainder of the observational studies,2 24–26 risk of 
bias was either low or unclear; exposure and outcome 
were measured accurately to reduce bias in most studies 
and follow-up deemed  long enough. The quality assess-
ment is available as supplementary information in online 
supplementary information 2.
Patient and study characteristics
Anxiety was measured using self-report questionnaires 
including the Hospital Anxiety and Depression Scale 
(HADS),27 the State-Trait Anxiety Inventory for Children 
(STAIC),28 Spence Children’s Anxiety Scale (SCAS)29 
and the Multidimensional Anxiety Scale for Children 
(MASC).30 One study used a diagnostic interview, the 
Development and Well-Being Assessment (DAWBA)31 
(see table 1).
Sample sizes ranged from 1 to 135 (see table 1) and 
ages ranged from 11 to 19 years. Most studies diagnosed 
participants according to the CDC criteria.15 The majority 
of participants were female in all of the studies, which 
is consistent with the epidemiology of adolescent CFS/
ME.32
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Table 2 Details of components in provided in CBT and behavioural interventions
Study Intervention
Duration and 
frequency
Chalder et 
al24
CBT-based rehabilitation programme including graded approach to increasing activity 
and establishing a sleep routine. Cognitive work was included where necessary.
Up to 15 hourly 
sessions, face to face
Diaz-Caneja 
et al23
CBT (no further details given)+fluoxetine (initially 10 mg daily, increased after 1 week to 
20 mg).
No details given.
Lloyd et al25
Rimes et al34
CBT which addressed unhelpful beliefs including fears about symptoms/activity. Activity 
diaries were used to establish a consistent routine and achieve a balance between 
activity and rest. The programme emphasised gradually increasing activities, including 
school, home, socialising and exercise and establishing a regular sleep routine. Social 
and emotional problems addressed if time allowed.
Up to 6×30 min 
sessions, by 
telephone, based on 
self-help manual
Nijhof et 
al22 33
CBT in the FITNET programme consisted of two sections, a psychoeducational section 
and CBT section. Parents had parallel modules.
21 interactive 
modules delivered 
via the internet, with 
e-consultations from 
therapists.
Wright et al20 STAIRway programme—appears to be a behavioural intervention. Sessions were 
spent developing a holistic understanding of CFS, formulating the vicious cycles that 
exacerbate fatigue, including nutrition, sleep patterns, physical deconditioning, social 
isolation, school non-attendance and emotional cycles. Adaptive coping strategies 
were developed, and negative attributions about illness and the future addressed. This 
was in addition to pacing activity to the changing needs and responses of the body by 
exercising to the point of tolerance and avoiding overexertion.
Approximately 18 
sessions over 1 year, 
beginning weekly 
and then gradually 
spacing out more. 
Face to face.
CBT, cognitive behavioural therapy; CFS, chronic fatigue syndrome; STAIRway, Structured Tailored Incremental Rehabilitation; FITNET , 
Fatigue In Teenagers on the interNET.
treatment in anxiety for children with cFs/Me
No studies specifically targeted anxiety in children with 
CFS/ME. Of the eight studies included, two2 26 were longi-
tudinal observational cohort studies. These two studies 
did not test an intervention and were therefore uninfor-
mative for establishing what is known about treatments 
for children with CFS/ME and anxiety.
Of the six treatment studies, four used a CBT approach, 
one used a behavioural approach and one used intrave-
nous gammaglobulin. The primary outcomes included 
fatigue20 22 24 25 33, disability or function23 and school 
attendance.20 22 24 25 33 34 All studies measured anxiety as a 
secondary outcome.
The common elements of all five cognitive behavioural 
and behavioural interventions appear to be the inclusion 
of a graded approach to managing activity and employing 
strategies to address cognitive elements such as illness-re-
lated beliefs and negative predictions about the future 
where necessary (see table 2 for details). Interventions 
varied considerably in the duration of treatment (12 
weeks to 1 year), length of sessions (no direct therapist 
contact/30 min/60 min) and treatment modality (face-
to-face, telephone, internet-delivered modules with ther-
apist e-consults).
studies using a cbt approach
The duration of CBT across the studies ranged from 6 to 
30 min telephone sessions at fortnightly intervals25 34 to 21 
internet session modules over 26 weeks.22 27 33 In three of 
the four studies, the authors report that anxiety improved 
with treatment, which suggests that cognitive behavioural 
treatment for CFS/ME may improve anxiety (table 3).
Nijhof et al’s RCT compared internet-based CBT 
with traditional methods in 135 participants. The inter-
net-based CBT, FITNET, includes psycho-educational 
modules for patients and parents in addition to CBT 
modules developed by the Expert Centre for Chronic 
Fatigue.22 33 Patients were able to send emails and ther-
apists replied to ‘e-consults’ on the same day each 
week or according to the treatment plan. At 6 months 
post-randomisation, the study demonstrated a signifi-
cant improvement in school attendance (full-time school 
75% in FITNET group compared with 16% in usual care 
group), fatigue and physical function in those receiving 
the FITNET intervention with 63% defined as ‘recovered’ 
compared with 8% of those receiving treatment as usual.
In the treatment study by Chalder et al, 23 participants 
were offered family-based CBT. There was a significant 
improvement in anxiety (measured using the HADS) at 
6 months (Median (IQR) 7 (6.7, 9.7) at assessment to 
0.5 (0.5, 9).24 The family-based CBT involved 15 fort-
nightly hourly sessions using a graded therapy method 
including a sleep routine and was implemented by 
patients and family with therapist guidance. The goal in 
this study was for children to return to full-time educa-
tion. Activity goals were set to include tasks such as 
walking, school work and attending social events. The 
activities were slowly increased and the aim to disasso-
ciating symptom relief with activity cessation. A sleep 
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routine was also established in addition to changing 
perceptions of their illness to prevent negative thoughts.
Lloyd et al trialled a telephone self-help interven-
tion involving 63 participants undergoing 6 fortnightly 
30 min sessions based on a CBT model that also showed 
a significant improvement in anxiety levels (treatment 
effect estimate −0.49 (CI −0.82 to 0.17), p=0.003).25 
This approach addressed any fears the participants 
had towards the programme in addition to completing 
activity diaries and developing a better sleep routine. 
Fatigue and school attendance were the primary 
outcomes, with anxiety being a secondary outcome 
measure.
Diaz-Caneja et al reported a moderate response to 
combined CBT and fluoxetine treatment in a single 
case study (n=1).23 They found that with this approach, 
there was increased tolerance to activity although the 
subject still felt tired. However, the specific components 
of treatment are not clear and the treatment appears to 
have been ongoing at the time of writing the case study.
study using a behavioural approach
Wright et al’s study was an RCT comparing two 
behavioural approaches, one called ‘pacing’ and the 
other ‘STAIRway to health’.20 Thirteen children were 
randomised into the treatment groups with stratifica-
tion for age, sex and mobility. The ‘pacing’ arm involved 
exercising to the child’s limits while adapting to an indi-
vidual’s bodily needs. The ‘STAIRway to health’ arm 
was a structured tailored incremental rehabilitation 
programme that took a more holistic approach to CFS/
ME aiming to treat both physical and psychological 
symptoms including nutrition, sleep, social activities 
and emotional issues.20 The clinic appointments were 
weekly for 1 month, fortnightly for the next 3 months, 
every third week for 2 months and every 4 weeks for 6 
months. STAIRway had a greater emphasis on coping 
strategies to deal with both the physical and psycho-
logical implications of CFS/ME and showed a greater 
improvement in anxiety levels.20
study using a pharmacological treatment
In the study by Rowe, 71 patients were recruited into 
an RCT comparing intravenous gammaglobulin to a 
placebo.23 Four domains were investigated, including 
school attendance, amount of school work attempted, 
amount of physical activities attempted and amount of 
social activities attempted. Anxiety reduced in all partic-
ipants at 6 months follow-up, both in those who were 
treated with the medication intravenous gammaglobulin 
and in those who received a placebo.23
Outcome for children with cFs/Me in those who are anxious 
versus those who are not
Neither the longitudinal observational cohort studies 
nor the treatment studies that assessed the outcome for 
children with CFS/ME who are anxious compared with 
those who were not. Some studies excluded those who 
were above a significant threshold for anxiety (Nijhof et 
al33) as shown in table 3.
Variation of outcome in children with cFs/Me and comorbid 
anxiety
None of the studies compared the outcome between 
those with and without anxiety.
DIscussIOn
This is the first systematic review to investigate the 
outcomes and treatment of children with CFS/ME who 
are also anxious. From this review, we know that treatment 
using a cognitive behavioural or behavioural approach 
led to improvements in self-reported anxiety at follow-up. 
However, the existing research is limited by the small 
sample sizes which are not powered to detect a treatment 
effect in the treatment of anxiety, inconsistency in the 
measurement of anxiety and the exclusion of patients 
with high levels of anxiety from some treatment trials.23
The strengths of this review include a thorough and 
wide-ranging search strategy by using a number of data-
bases in addition to hand-searching articles. Five reviewers 
carried out screening, with at least two reviewers screening 
at each stage. An additional reviewer was consulted to 
resolve differences of opinion. Foreign language papers 
were included with the help of native speakers to aid in 
translation.
Only eight studies were found with most having small 
sample sizes. None were powered to determine treatment 
efficacy in those with CFS/ME and anxiety. Only three of 
the studies were RCTs and one excluded those with high 
anxiety scores,19 20 22 33 making it difficult to investigate 
treatment effects in those with comorbid anxiety. None of 
the studies included children who were 10 years old and 
younger and therefore we do not know about treatment 
efficacy in this group.33
It is difficult to determine from the results of these 
studies whether anxiety scores have improved due to 
regression to the mean, anxiety reducing on its own 
without intervention or whether the treatment itself is 
having an effect. Improvements in functioning may lead 
to increased exposure to anxiety provoking situations (for 
example, school), resulting in a habituation response. 
Therefore, it is not possible to ascertain the extent to 
which treatment was responsible for improvements, 
given the lack of robust studies, designed to specifically 
compare treatment for anxiety in paediatric CFS/ME 
patients to waiting list controls (or an alternative treat-
ment/usual care).
The improvements in anxiety reported in the study by 
Rowe in both the pharmacological treatment arm and the 
placebo arm suggests that anxiety in CFS/ME may natu-
rally decrease over time without active intervention.23 
This finding may be explained by the mean functional 
improvement that demonstrated a significant reduc-
tion in both groups; that is, anxiety might improve as a 
result of functionally improving. However, this is difficult 
 o
n
 21 June 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2016-015481 on 5 September 2017. Downloaded from 
10 Stoll SVE, et al. BMJ Open 2017;7:e015481. doi:10.1136/bmjopen-2016-015481
Open Access 
to disentangle as both groups received information on 
education and social support services in this study, and 
this in itself may have been an active intervention that led 
to changes in functioning and anxiety.23
For children without comorbid physical health condi-
tions who present for treatment of anxiety, various inter-
ventions have shown to be effective, including CBT, 
bibliotherapy (parents given a type of instruction manual 
to aid their children’s’ anxiety) and e-therapies (comput-
erised programme).35 However, whether these therapies 
will be effective in paediatric CFS/ME is uncertain. As 
rates of anxiety are increased in children with CFS/ME, 
by remediating their fatigue, anxiety may decrease.8
This review did not identify any studies that clarify the 
impact of anxiety on outcome in CFS/ME (with or without 
treatment). In adults with CFS/ME, one study has found 
that anxiety improved in CFS/ME patients receiving CBT, 
graded exercise therapy and activity management.36 In 
other childhood chronic illnesses such as inflammatory 
bowel disease, CBT techniques have shown to be bene-
ficial.37 CBT has also been found to be effective for chil-
dren with type 1 diabetes.38 A systematic review concluded 
that despite weak evidence, CBT is beneficial in children 
with chronic physical illness and comorbid anxiety.39 On 
this basis, and as CBT has been found to be successful for 
anxiety in children in the general population, this does 
seem like the most promising approach. Further research 
to determine the impact of anxiety on recovery, and if 
necessary, to adapt CBT for CFS/ME to include anxiety 
management components, would be beneficial.
cOnclusIOn
Paediatric CFS/ME is a severe debilitating illness causing 
significant levels of school absence. About a third of chil-
dren with CFS/ME have high levels of anxiety. We wanted 
to find out what was known about treatment approaches 
for anxiety in children with CFS/ME and what is known 
about the impact of comorbid anxiety on outcome in 
CFS/ME. While CBT appears to result in lower levels 
of anxiety at follow-up, there was insufficient evidence 
to conclude what the best treatment is for dealing with 
anxiety in paediatric CFS/ME patients.
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